United Therapeutics Corp
UTHR
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 6, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
72.7% upsideUndervalued by 72.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.64 Billion |
|---|---|
| Enterprise Value | $22.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $30.13 |
| Beta | 0.6 |
| Outstanding Shares | 43,500,000 |
Return
| Return on Equity | 21.82% |
|---|---|
| Return on Assets | 19.17% |
| Return on Invested Capital | 25.44% |
Valuation & Multiples
| P/E Ratio | 18.81 |
|---|---|
| PEG | -128.16 |
| Price to Sales | 7.63 |
| Price to Book Ratio | 4.07 |
| Enterprise Value to Revenue | 7.12 |
| Enterprise Value to EBIT | 14.5 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7411▼ 17.12% |
|---|---|
| Total Calls | 2,078,102▲ 181.43% |
| Total Puts | 1,540,151▲ 128.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 93.64%▼ 1.29% |
|---|---|
| Total Invested | $24.56B▲ 21.36% |
| Investors Holding | 886▲ 32.00% |
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...
Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending. It drives corporate valuations through tax policy and significantly impacts the pharmaceutical sector through Medicare and Medicaid pricing and reimbursement policies, which are critical revenue determinants for drug companies.
This committee allocates discretionary federal spending. Its subcommittees directly determine funding for health-related agencies (e.g., NIH, CDC) and government programs that may purchase United Therapeutics' products or fund research relevant to its pipeline, directly affecting cash flow.
This is a primary committee for United Therapeutics. It regulates the FDA (drug approvals, manufacturing standards) and NIH (research funding), directly impacting the development, approval, and commercialization pathways for pharmaceutical and biotech products.
This committee oversees antitrust laws and intellectual property. Patent protection is absolutely critical for pharmaceutical companies like United Therapeutics, and antitrust enforcement can impact mergers, acquisitions, and market competition within the industry.